{"schema_version":"secwatch.filing_event.v1","accession":"0001193805-26-001039","form_type":"8-K","ticker":"ARCT","cik":"0001768224","company_name":"Arcturus Therapeutics Holdings Inc.","filed_at":"2026-08-06T20:06:01+00:00","discovered_at":"2026-08-06T20:07:10.269219+00:00","generated_at":"2026-08-06T20:07:17.357514+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Arcturus Q2 net loss $23.8M; regains KOSTAIVE rights; ARCT-032 Phase 3 decision Q4 2026","bullets":["Net loss of $23.8M ($0.84/share) vs $9.2M ($0.34/share) in Q2 2025; revenue fell to $3.0M from $28.3M due to CSL Seqirus termination.","Regained global rights to KOSTAIVE and infectious disease portfolio from CSL Seqirus; received $12M cash and $16M in released liabilities.","ARCT-032 (CF) Phase 2 enrollment on schedule; decision to proceed to Phase 3 expected Q4 2026; Thermo Fisher collaboration for Phase 3.","ARCT-810 (OTC deficiency) Phase 2 enrollment and dosing completed; data and regulatory plan expected Q3 2026.","Cash and cash equivalents $191.5M as of June 30, 2026; cash runway over 2.5 years through year end 2028."],"urls":{"canonical":"https://secwatch.observer/filing/0001193805-26-001039","json":"https://secwatch.observer/filing/0001193805-26-001039.json","markdown":"https://secwatch.observer/filing/0001193805-26-001039.md","text":"https://secwatch.observer/filing/0001193805-26-001039.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1768224/000119380526001039/0001193805-26-001039-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1768224/000119380526001039/e665679_8k-arct.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-08-06T20:07:17.357514+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}